Weekly profile.HYTHIAM INC inc - /ink/ increment, i.e. increase by one. Especially used by assembly programmers, as many assembly languages have an "inc" mnemonic. Antonym: dec. . (HYTM) Business Overview Hythiam Inc. researches, develops licenses and commercializes physiological treatment protocols designed for use by healthcare providers to treat individuals diagnosed with dependencies to alcohol, cocaine cocaine (kōkān`, kō`kān), alkaloid drug derived from the leaves of the coca shrub. A commonly abused illegal drug, cocaine has limited medical uses, most often in surgical applications that take advantage of the fact that, in and methamphetamine methamphetamine (mĕth'ămfĕt`əmēn): see amphetamine; methedrine. , as well as combinations of these drugs. Unlike traditional treatment methodologies, the company's PROMETA treatment protocols include medically supervised su·per·vise tr.v. su·per·vised, su·per·vis·ing, su·per·vis·es To have the charge and direction of; superintend. [Middle English *supervisen, from Medieval Latin treatments designed to address both the neurochemical neu·ro·chem·is·try n. The study of the chemical composition and processes of the nervous system and the effects of chemicals on it. neu imbalances in the brain and some of the nutritional deficits caused or worsened by substance dependence. During the year ended December 31, 2005, Hythiam commenced the management of PROMETA Center Inc., an affiliated medical practice operating outpatient facility in California. Its primary focus is on offering PROMETA protocols for dependencies on alcohol, cocaine and methamphetamines but will also offers medical interventions for other substance dependencies, including buprenorphine therapy for the treatment of opiate opiate /opi·ate/ (o´pe-it) 1. any drug derived from opium. 2. hypnotic (2). o·pi·ate n. 1. dependence. WEEKLY PROFILE Income Statement Revenue (millions) $1.6 $1.2 Operating Income (millions) (29.6) (24.9) Net Income (millions) (28.4) (24.0) EPS ($0.84) ($0.77) Summary Headquarters: Los Angeles Market Cap: $216.96 million Dividend Yield: N/A P/E Ratio: N/A * Latest Twelve Months Ending 312006 ** Fiscal Year Ending 12/2005 [GRAPHIC OMITTED] |
|
||||||||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion